bluuebunny/crossref_metadata_2025 huggingface dataset:
Intraoperative fluorescence detection and resection of a lymph node containing ovarian cancer metastases from A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer
Authors: Hoogstins Charlotte E.S. , Tummers Quirijn R.J.G. , Gaarenstroom Katja N. , de Kroon Cor D. , Trimbos J. Baptist M.Z. , Bosse Tjalling , Smit Vincent T.H.B.M. , Vuyk Jaap , van de Velde Cornelis J.H. , Cohen Adam F. , Low Philip S. , Burggraaf Jacobus , Vahrmeijer Alexander L.
Published: April 2023

Intraoperative fluorescence detection and resection of a lymph node containing ovarian cancer metastases from A Novel Tumor-Specific Agent for Intraoperative Near-Infrared Fluorescence Imaging: A Translational Study in Healthy Volunteers and Patients with Ovarian Cancer
Supplementary Table S1 and Figure Legends from Personalized Preclinical Trials in BRAF Inhibitor–Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies
Authors: Krepler Clemens , Xiao Min , Sproesser Katrin , Brafford Patricia A. , Shannan Batool , Beqiri Marilda , Liu Qin , Xu Wei , Garman Bradley , Nathanson Katherine L. , Xu Xiaowei , Karakousis Giorgos C. , Mills Gordon B. , Lu Yiling , Ahmed Tamer A. , Poulikakos Poulikos I. , Caponigro Giordano , Boehm Markus , Peters Malte , Schuchter Lynn M. , Weeraratna Ashani T. , Herlyn Meenhard
Published: April 2023

Supplementary Table S1: Summary of melanoma patients with clinical follow-up. Figure Legends
Supplementary Table S4 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

Correlative analysis of PFS and OS with the expression of biomarkers using the 25th percentile and median marker distributions as cutpoints: total IR, IR-A, IR-B, and IGF-1R in pooled group and arm A
Supplementary Table S3 from Clinical and Translational Results of a Phase II, Randomized Trial of an Anti–IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy
Authors: Gradishar William J. , Yardley Denise A. , Layman Rachel , Sparano Joseph A. , Chuang Ellen , Northfelt Donald W. , Schwartz Gary N. , Youssoufian Hagop , Tang Shande , Novosiadly Ruslan , Forest Amelie , Nguyen Tuan S. , Cosaert Jan , Grebennik Dmitri , Haluska Paul
Published: April 2023

Correlative analysis of PFS and OS with the expression of biomarkers using the 75th percentile of marker distribution as cutpoint: Total IR, IR-A, IR-B, and IGF-1R in pooled group and arm A
Supplemental Figures 1-3, Tables 1-3 from Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group
Authors: Laszlo George S. , Alonzo Todd A. , Gudgeon Chelsea J. , Harrington Kimberly H. , Gerbing Robert B. , Wang Yi-Cheng , Ries Rhonda E. , Raimondi Susana C. , Hirsch Betsy A. , Gamis Alan S. , Meshinchi Soheil , Walter Roland B.
Published: April 2023

Supplemental Figures 1-3, Tables 1-3. Supplemental Figure 1. Highly variable expression of MMRN1 in pediatric AML patient specimens. Supplemental Figure 2. Clinical outcome in patients with high and low MMRN1 expression. Supplemental Figure 3. Relationship between bone marrow blast percentage and MMRN1 expression in the AAML0531 patient cohort. SUPPLEMENTAL TABLE 1. Comparison of Baseline Characteristics of Patients with Low (<0.5) vs. High (â‰¥0.5) MMRN1 Expression in AAML03P1. SUPPLEMENTAL TABLE 2. Univariate and Multivariate Regression Models of OS, EFS, and RR for the AAML0531 Study, with Outcome Censored at Time of HCT. SUPPLEMENTAL TABLE 3. Relative MMRN1 expression in paired samples of CD34+/CD33- and CD34+/CD33+ cells.
Supplemental Methods from Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer
Authors: Moon Edmund K. , Ranganathan Raghuveer , Eruslanov Evgeniy , Kim Soyeon , Newick Kheng , O'Brien Shaun , Lo Albert , Liu Xiaojun , Zhao Yangbing , Albelda Steven M.
Published: April 2023

Description of cell culture conditions, isolation/activation/transduction/expansion of T cells, generation of target cell lines, flow cytometric conditions, ELISA measurements, statistical analyses, and animal use.
Supplemental figure 2 - Linearity from The Prognostic and Predictive Value of Soluble Type IV Collagen in Colorectal Cancer: A Retrospective Multicenter Study
Authors: Rolff Hans Christian , Christensen Ib Jarle , Vainer Ben , Svendsen Lars Bo , Eefsen Rikke Løvendahl , Wilhelmsen Michael , Lund Ida Katrine , Høyer-Hansen Gunilla , Nielsen Hans Jørgen , Illemann Martin
Published: April 2023

Shows the result of the linearity experiment. Figure legend in the end the "Supplementary data. Appendix 2. Assay validation" file
Supplementary Tables S1-S3 and Table Legends from Cyclin-Dependent Kinase 5 Decreases in Gastric Cancer and Its Nuclear Accumulation Suppresses Gastric Tumorigenesis
Authors: Cao Longlong , Zhou Jiechao , Zhang Junrong , Wu Sijin , Yang Xintao , Zhao Xin , Li Huifang , Luo Ming , Yu Qian , Lin Guangtan , Lin Huizhong , Xie Jianwei , Li Ping , Hu Xiaoqing , Zheng Chaohui , Bu Guojun , Zhang Yun-wu , Xu Huaxi , Yang Yongliang , Huang Changming , Zhang Jie
Published: April 2023

Supplementary Tables S1-S3 and Table Legends. Table S1. Clinicopathological parameters of gastric cancer patients with Low or High CDK5 Expression. Table S2. Univariate analysis of the correlation between clinicopathological parameters and survival of patients with gastric cancer. Table S3. Multivariate Analysis of the Correlation between Clinicopathological Parameters and Survival Time of Patients with Gastric Cancer.
Supplementary Methods. Supplementary Tables S1-7. Supplementary Figures S1 and S2 from Assessment of EGFR Mutation Status in Matched Plasma and Tumor Tissue of NSCLC Patients from a Phase I Study of Rociletinib (CO-1686)
Authors: Karlovich Chris , Goldman Jonathan W. , Sun Jong-Mu , Mann Elaina , Sequist Lecia V. , Konopa Krzysztof , Wen Wei , Angenendt Philipp , Horn Leora , Spigel David , Soria Jean-Charles , Solomon Benjamin , Camidge D. Ross , Gadgeel Shirish , Paweletz Cloud , Wu Lin , Chien Sean , O'Donnell Patrick , Matheny Shannon , Despain Darrin , Rolfe Lindsey , Raponi Mitch , Allen Andrew R. , Park Keunchil , Wakelee Heather
Published: April 2023

Supplementary Tables S1-7. Supplementary Table S1. Clinical characteristics of patients in the present analysis. Supplementary Table S2. Plasma/tissue concordance results for del19 and L858R mutations. Supplementary Table S3. EGFR mutations identified in tissue and plasma by the cobasÃƒâ€šÃ‚Â® EGFR mutation test. Supplementary Table S4. Concordance between tumor and BEAMing plasma EGFR status. Supplementary Table S5. Overall concordance between cobasÃƒâ€šÃ‚Â® and BEAMing EGFR mutation tests. Supplementary Table S6. Platform Comparison of T790M tests in a sample set enriched for low copy plasma cases. Supplementary Table S7. EGFR mutation detection by cobasÃƒâ€šÃ‚Â® plasma test and NSCLC disease classification (n = 72) Supplementary Figures S1-2. Supplementary Figure S1. Tumor burden is a weak predictor of ability to detect EGFR mutations in plasma. Supplementary Figure S2. T790M to activating mutation ratio in plasma is associated with depth of response to rociletinib.
Figure S6 from β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer
Authors: San Millán Coral , Soldevilla Beatriz , Martín Paloma , Gil-Calderón Beatriz , Compte Marta , Pérez-Sacristán Belén , Donoso Encarnación , Peña Cristina , Romero Jesús , Granado-Lorencio Fernando , Bonilla Félix , Domínguez Gemma
Published: April 2023

Figure S6. Quantification of Î”Np73 mRNA levels in normal colon mucosa from mice after the treatment with vehicle, Î²-cryptoxanthin 10 Î¼M, oxaliplatin 3 mg/Kg and the combined regimen of Î²-cryptoxanthin 10 Î¼M and oxaliplatin 3 mg/Kg. Mean {plus minus} standard deviation of at least four samples per group is represented.
Figure S4 from β-Cryptoxanthin Synergistically Enhances the Antitumoral Activity of Oxaliplatin through ΔNP73 Negative Regulation in Colon Cancer
Authors: San Millán Coral , Soldevilla Beatriz , Martín Paloma , Gil-Calderón Beatriz , Compte Marta , Pérez-Sacristán Belén , Donoso Encarnación , Peña Cristina , Romero Jesús , Granado-Lorencio Fernando , Bonilla Félix , Domínguez Gemma
Published: April 2023

Figure S4. Quantification of cell viability by MTT assay. Combined treatment of 50 and 20 ÂµM oxaliplatin and 10 ÂµM Î²-cryptoxanthin in (A) HCT116 and (B) SW480-ADH cells respectively, leads to similar percentage of cell viability reduction to those produced by a double dose of oxaliplatin. * p<0.05, **p<0.01. Mean {plus minus} standard deviation of at least three independent experiments is represented.
Supplemental Table 1 from Alternate Metabolic Programs Define Regional Variation of Relevant Biological Features in Renal Cell Carcinoma Progression
Authors: Brooks Samira A. , Khandani Amir H. , Fielding Julia R. , Lin Weili , Sills Tiffany , Lee Yueh , Arreola Alexandra , Milowsky Mathew I. , Wallen Eric M. , Woods Michael E. , Smith Angie B. , Nielsen Mathew E. , Parker Joel S. , Lalush David S. , Rathmell W. Kimryn
Published: April 2023

Demographics of patients used in PET/MR study
Supplemental Figure Legends from CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Authors: Olanich Mary E. , Sun Wenyue , Hewitt Stephen M. , Abdullaev Zied , Pack Svetlana D. , Barr Frederic G.
Published: April 2023

Supplemental Figure Legends
Supplemental Figure 3 from CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Authors: Olanich Mary E. , Sun Wenyue , Hewitt Stephen M. , Abdullaev Zied , Pack Svetlana D. , Barr Frederic G.
Published: April 2023

Supplemental Figure 3. Further evaluation of CDK4/6 inhibitor sensitivity in fusion-positive and fusion-negative RMS cells.
Supplementary Patients and Methods, Supplementary References, Supplementary Tables 1-6, Supplementary Figures 1-5 from Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation–Associated Breast Cancer
Authors: Rodler Eve T. , Kurland Brenda F. , Griffin Melissa , Gralow Julie R. , Porter Peggy , Yeh Rosa F. , Gadi Vijayakrishna K. , Guenthoer Jamie , Beumer Jan H. , Korde Larissa , Strychor Sandra , Kiesel Brian F. , Linden Hannah M. , Thompson John A. , Swisher Elizabeth , Chai Xiaoyu , Shepherd Stacie , Giranda Vincent , Specht Jennifer M.
Published: April 2023

Table S1: Schedule of pharmacokinetic analysis; Table S2: Overview of study dose levels (N=50); Table S3. Adverse events reported at any time during study therapy: grade 3-4 adverse events; Table S4: Veliparib pharmacokinetic (PK) parameters by cohort; Table S5: Total and ultrafilterable platinum pharmacokinetic parameters by cohort; Table S6: Immunohistochemistry results for 28 pre-therapy samples; Figure S1: Veliparib Cmax (ng/mL, panel A) and veliparib AUC0-6 (hr*ng/mL, panel B) by dose Cohort; Figure S2: Veliparib pharmacokinetic parameters (A) Cmax and (B) AUC0-6 at cycles 1 and 4 by cohort; Figure S3: Ultrafilterable platinum pharmacokinetic parameters Cmax and AUC0-24 at cycles 1 and 4 by cohort; Figure S4: Consort 2010 flow diagram for exploratory efficacy analysis comparing germline BRCA mutation positive to wild type; Figure S5: PAR assay results (pg/mL) for 14 patients in dose cohorts 6-8 (120-200 mg)
Supplementary 3 from A Novel Anti-CD22 Anthracycline-Based Antibody–Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs
Authors: Yu Shang-Fan , Zheng Bing , Go MaryAnn , Lau Jeff , Spencer Susan , Raab Helga , Soriano Robert , Jhunjhunwala Suchit , Cohen Robert , Caruso Michele , Polakis Paul , Flygare John , Polson Andrew G.
Published: April 2023

Supplementary 3. Cell lines derived from xenograft tumors resistant to anti-CD22-vc-MMAE were resistance to anti-CD22-vc-MMAE
Supplementary Figure Legends (Figures 1-6) from Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer
Authors: Gonzalez-Villasana Vianey , Fuentes-Mattei Enrique , Ivan Cristina , Dalton Heather J. , Rodriguez-Aguayo Cristian , Fernandez-de Thomas Ricardo J. , Aslan Burcu , del C. Monroig Paloma , Velazquez-Torres Guermarie , Previs Rebecca A. , Pradeep Sunila , Kahraman Nermin , Wang Huamin , Kanlikilicer Pinar , Ozpolat Bulent , Calin George , Sood Anil K. , Lopez-Berestein Gabriel
Published: April 2023

Supplementary Figure Legends (Figures 1-6)
Supplemental Table II from Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Authors: Donnem Tom , Hald Sigurd M. , Paulsen Erna-Elise , Richardsen Elin , Al-Saad Samer , Kilvaer Thomas K. , Brustugun Odd Terje , Helland Aslaug , Lund-Iversen Marius , Poehl Mette , Olsen Karen Ege , Ditzel Henrik J. , Hansen Olfred , Al-Shibli Khalid , Kiselev Yury , Sandanger Torkjel M. , Andersen Sigve , Pezzella Francesco , Bremnes Roy M. , Busund Lill-Tove
Published: April 2023

Supplemental Table II. Prognostic clinicopathologic variables as predictors for DFS in 797 NSCLS (univariate analysis,log-rank test)
Supplementary Figure Legends from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

legends for supplementary figures
Supplemental Figure 2 from The Hippo Coactivator YAP1 Mediates EGFR Overexpression and Confers Chemoresistance in Esophageal Cancer
Authors: Song Shumei , Honjo Soichiro , Jin Jiankang , Chang Shih-Shin , Scott Ailing W. , Chen Qiongrong , Kalhor Neda , Correa Arlene M. , Hofstetter Wayne L. , Albarracin Constance T. , Wu Tsung-Teh , Johnson Randy L. , Hung Mien-Chie , Ajani Jaffer A.
Published: April 2023

Supplemental Figure 2. Knock down EGFR in induced YAP1 overexpressed EC cells significantly reduced EC cell growth
Supplementary Figure 3 from Optimal Patient Selection for Trastuzumab Treatment in HER2-Positive Advanced Gastric Cancer
Authors: Ock Chan-Young , Lee Keun-Wook , Kim Jin Won , Kim Jin-Soo , Kim Tae-Yong , Lee Kyung-Hun , Han Sae-Won , Im Seock-Ah , Kim Tae-You , Kim Woo Ho , Bang Yung-Jue , Oh Do-Youn
Published: April 2023

Supplementary Figure 3. Receiver operating characteristic curves of HER2 gene copy number according to HER2 IHC status.
Supplementary table 1 from Reduced Expression of SMAD4 Is Associated with Poor Survival in Colon Cancer
Authors: Yan Pu , Klingbiel Dirk , Saridaki Zenia , Ceppa Paola , Curto Monica , McKee Thomas Alexander , Roth Arnaud , Tejpar Sabine , Delorenzi Mauro , Bosman Fredrik T. , Fiocca Roberto
Published: April 2023

Correlation between SMAD4 expression and FOLFIRI and 5-FU/FA treatment
Supplementary Table S1 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

Combination therapy with JQ1 and panobinostat exerts synergistic anticancer effects in neuroblastoma cells.
Supplementary Figure S2 from The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects
Authors: Shahbazi Jeyran , Liu Pei Y. , Atmadibrata Bernard , Bradner James E. , Marshall Glenn M. , Lock Richard B. , Liu Tao
Published: April 2023

The BET bromodomain protein BRD2 does not regulate N-Myc expression.
Supplementary Table 2 from Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression
Authors: Satelli Arun , Mitra Abhisek , Brownlee Zachary , Xia Xueqing , Bellister Seth , Overman Michael J. , Kopetz Scott , Ellis Lee M. , Meng Qing H. , Li Shulin
Published: April 2023

Supplementary Table 2. Diagnostic cutoff
Supplementary Figure 2 from Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression
Authors: Satelli Arun , Mitra Abhisek , Brownlee Zachary , Xia Xueqing , Bellister Seth , Overman Michael J. , Kopetz Scott , Ellis Lee M. , Meng Qing H. , Li Shulin
Published: April 2023

Supplementary Figure 2. ROC curves for CTC counts using CSV: ROC curves were determined to discriminate the responding/ stable patients from that of the non-responding/ progressive metastatic colon cancer patients. An AUC-ROC value of closer to 1 denotes a perfect method for discrimination.
Supplementary Figure S5 from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Figure S5. C086 treatment does not affect the engraftment of normal bone marrow cells in NOD-SCID mice.
Supplementary Figure S4 from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Figure S4. C086 potently inhibits the growth of human leukemia progenitor/stem cells.
Supplementary Figure 1 from Epithelial–Mesenchymal Transitioned Circulating Tumor Cells Capture for Detecting Tumor Progression
Authors: Satelli Arun , Mitra Abhisek , Brownlee Zachary , Xia Xueqing , Bellister Seth , Overman Michael J. , Kopetz Scott , Ellis Lee M. , Meng Qing H. , Li Shulin
Published: April 2023

Supplementary Figure 1. Cell surface vimentin expression is limited to cancer cells. Cell surface staining analysis for CSV in cancer cell line HLM-3 (liver cancer; top) and normal cell line NCM-356 (normal colon; bottom) using confocal microscopy. Permeabilized cells were stained for CSV (with 84-1 antibody; green), nuclei (with nuclear stain DRAQ5; blue), and the cell-surface marker WGA (red). 84-1 binding indicates cell surface vimentin that co-localizes with WGA. Scale bar, 10 µm.
Supplementary Figure S2 from Dual Inhibition of Bcr-Abl and Hsp90 by C086 Potently Inhibits the Proliferation of Imatinib-Resistant CML Cells
Authors: Wu Lixian , Yu Jing , Chen Ruijia , Liu Yang , Lou Liguang , Wu Ying , Huang Lisen , Fan Yingjuan , Gao Pinzhang , Huang Meijuan , Wu Yong , Chen Yuanzhong , Xu Jianhua
Published: April 2023

Supplementary Figure S2. C086 triggers the mitochondrial pathway of apoptosis in CML cells.
Supplementary Table 4 from Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vathipadiekal Vinod , Wang Victoria , Wei Wei , Waldron Levi , Drapkin Ronny , Gillette Michael , Skates Steven , Birrer Michael
Published: April 2023

Supplementary Table 4. Pathway associated probesets up-regulated in cancer as compared to both normal fallopian and ovarian surface epithelium.
Supplemental Figure S5 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
Authors: Bowers Jacob S. , Nelson Michelle H. , Kundimi Sreenath , Bailey Stefanie R. , Huff Logan W. , Schwartz Kristina M. , Cole David J. , Rubinstein Mark P. , Paulos Chrystal M.
Published: April 2023

Supplemental Figure S5. Priming Tc17 cells with IL-12 does not increase their engraftment in the spleen.
Supplementary Table 3 from Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vathipadiekal Vinod , Wang Victoria , Wei Wei , Waldron Levi , Drapkin Ronny , Gillette Michael , Skates Steven , Birrer Michael
Published: April 2023

Supplementary Table 3. List of pathways identified for the statistically significant up-regulated probesets in cancer as compared to normal ovarian surface epithelium.
Supplemental Figure S4 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
Authors: Bowers Jacob S. , Nelson Michelle H. , Kundimi Sreenath , Bailey Stefanie R. , Huff Logan W. , Schwartz Kristina M. , Cole David J. , Rubinstein Mark P. , Paulos Chrystal M.
Published: April 2023

Supplemental Figure S4. TBI transiently enhances activation of dendritic cells in the spleen.
Supplementary Methods from Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array
Authors: Vathipadiekal Vinod , Wang Victoria , Wei Wei , Waldron Levi , Drapkin Ronny , Gillette Michael , Skates Steven , Birrer Michael
Published: April 2023

Supplementary Methods
Supplemental Figure Legend from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
Authors: Bowers Jacob S. , Nelson Michelle H. , Kundimi Sreenath , Bailey Stefanie R. , Huff Logan W. , Schwartz Kristina M. , Cole David J. , Rubinstein Mark P. , Paulos Chrystal M.
Published: April 2023

Supplemental Figure Legend
Supplementary Fig. S6 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Fig. S6. Phylogenies inferred from the high-confident mutations. (A) The phylogenetic trees inferred from the high-confident mutations or those called in the regions with high sequencing coverage (>50X) are shown for five CRC cases. (B) For comparison, the phylogenetic trees of main Figure 4 are shown.
Supplementary Table 1 from An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Authors: Danial Christina , Sarin Kavita Y. , Oro Anthony E. , Chang Anne Lynn S.
Published: April 2023

functional resistance in vitro and SMO mutations found in study subjects. (a) SMO mutations with previously demonstrated functional resistance in vitro to Smoothened inhibitors, including vismodegib and sonidegib. Shaded cells indicate mutations that have been reported as resistant to sonidegib and found in one of the subjects' tumors in the current trial.(b) SMO mutations found in subjects' BCCs but not known to be functionally resistant in the literature.
Supplementary Figure 1 from An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
Authors: Danial Christina , Sarin Kavita Y. , Oro Anthony E. , Chang Anne Lynn S.
Published: April 2023

Swimmer's plot showing resistance to vismodegib of study patients.
Supplementary Fig. S2 from Subclonal Genomic Architectures of Primary and Metastatic Colorectal Cancer Based on Intratumoral Genetic Heterogeneity
Authors: Kim Tae-Min , Jung Seung-Hyun , An Chang Hyeok , Lee Sung Hak , Baek In-Pyo , Kim Min Sung , Park Sung-Won , Rhee Je-Keun , Lee Sug-Hyung , Chung Yeun-Jun
Published: April 2023

Supplementary Fig. S2. Fraction of biopsy-specific mutations. Per biopsy, the percentage (%) of mutations that are not observed in any other regions in a given sample are shown. Black and purple bars represent primary and metastatic tumors, respectively.
Supplemental Figure 1 from Chaperonin Containing TCP-1 Protein Level in Breast Cancer Cells Predicts Therapeutic Application of a Cytotoxic Peptide
Authors: Bassiouni Rania , Nemec Kathleen N. , Iketani Ashley , Flores Orielyz , Showalter Anne , Khaled Amr S. , Vishnubhotla Priya , Sprung Robert W. , Kaittanis Charalambos , Perez Jesus M. , Khaled Annette R.
Published: April 2023

Supplemental figure showing IHC scoring scheme
Supplementary Figure Legends from PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis
Authors: Jilaveanu Lucia B. , Parisi Fabio , Barr Meaghan L. , Zito Christopher R. , Cruz-Munoz William , Kerbel Robert S. , Rimm David L. , Bosenberg Marcus W. , Halaban Ruth , Kluger Yuval , Kluger Harriet M.
Published: April 2023

This file provides legends for Supplementary Figures S1, S2, S3 and S4. Figure S1 contains Kaplan Meier survival curves for PLEKHA5 expression and metastases to various sites, Figures S2 and S3 show Western blots demonstrating PLEKHA5 expression in cells transfected and untransfected with siRNA for PLEKHA5, and Figure S4 shows the effect of astrocytes on PLEKHA5 silencing and cell viability in A375Br cells.
Supplemental Note 1 from Zinc Finger Nucleases Targeting the Human Papillomavirus E7 Oncogene Induce E7 Disruption and a Transformed Phenotype in HPV16/18-Positive Cervical Cancer Cells
Authors: Ding Wencheng , Hu Zheng , Zhu Da , Jiang Xiaohui , Yu Lan , Wang Xiaoli , Zhang Changlin , Wang Liming , Ji Teng , Li Kezhen , He Dan , Xia Xi , Liu Dan , Zhou Jianfeng , Ma Ding , Wang Hui
Published: April 2023

The amino acid sequences of FokI variants.
Supplementary Table 1 from Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia
Authors: Janovska Pavlina , Poppova Lucie , Plevova Karla , Plesingerova Hana , Behal Martin , Kaucka Marketa , Ovesna Petra , Hlozkova Michaela , Borsky Marek , Stehlikova Olga , Brychtova Yvona , Doubek Michael , Machalova Michaela , Baskar Sivasubramanian , Kozubik Alois , Pospisilova Sarka , Pavlova Sarka , Bryja Vitezslav
Published: April 2023

Supplementary Table 1. Expression of WNT5A and WNT5B in individual patient groups
Supplementary Figure 3 from MicroRNA-374b Suppresses Proliferation and Promotes Apoptosis in T-cell Lymphoblastic Lymphoma by Repressing AKT1 and Wnt-16
Authors: Qian Dong , Chen Kailin , Deng Haixia , Rao Huilan , Huang Huiqiang , Liao Yiji , Sun Xiaofei , Lu Suying , Yuan Zhiyong , Xie Dan , Cai Qingqing
Published: April 2023

The effect of Replenishment of Wnt16b and AKT1 on cell growth and apoptosis in SUP-T1-374b cells
Table S2 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

Total read count, percentage of aligned reads and number of peaks for each ChIP-seq.
Table S1 from SRC3 Phosphorylation at Serine 543 Is a Positive Independent Prognostic Factor in ER-Positive Breast Cancer
Authors: Zwart Wilbert , Flach Koen D. , Rudraraju Bharath , Abdel-Fatah Tarek M.A. , Gojis Ondrej , Canisius Sander , Moore David , Nevedomskaya Ekaterina , Opdam Mark , Droog Marjolein , Hofland Ingrid , Chan Steve , Shaw Jacqui , Ellis Ian O. , Coombes R. Charles , Carroll Jason S. , Ali Simak , Palmieri Carlo
Published: April 2023

QPCR primer sequences for ChIP validations.
Supplementary Table 3 from Identification of Biological Relevant Minor Histocompatibility Antigens within the B-lymphocyte–Derived HLA-Ligandome Using a Reverse Immunology Approach
Authors: Hombrink Pleun , Hassan Chopie , Kester Michel G.D. , Jahn Lorenz , Pont Margot J. , de Ru Arnoud H. , van Bergen Cornelis A.M. , Griffioen Marieke , Falkenburg J.H. Frederik , van Veelen Peter A. , Heemskerk Mirjam H.M.
Published: April 2023

Supplementary Table 3. Expanded T-cell lines after first MHC-multimer pull down. Expanded T-cell lines after second MHC-multimer pull down.
Supplementary Tables 1 - 3 from Alterations Associated with Androgen Receptor Gene Activation in Salivary Duct Carcinoma of Both Sexes: Potential Therapeutic Ramifications
Authors: Mitani Yoshitsugu , Rao Pulivarthi H. , Maity Sankar N. , Lee Yu-Chen , Ferrarotto Renata , Post Julian C. , Licitra Lisa , Lippman Scott M. , Kies Merrill S. , Weber Randal S. , Caulin Carlos , Lin Sue-Hwa , El-Naggar Adel K.
Published: April 2023

Supplementary Table S1. PCR primer sequences in this study. Supplementary Table S2. AR IHC and FISH result Supplementary Table S3. AR mutation detail result in this study.
Supplementary information from Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation
Authors: Couch Jessica A. , Zhang Gu , Beyer Joseph C. , de Zafra Christina L. Zuch , Gupta Priyanka , Kamath Amrita V. , Lewin-Koh Nicholas , Tarrant Jacqueline , Allamneni Krishna P. , Cain Gary , Yee Sharon , Ross Sarajane , Cook Ryan , Tsai Siao Ping , Ruppel Jane , Ridgway John Brady , Paluch Maciej , Hass Philip E. , Franklin Jayme , Yan Minhong
Published: April 2023

Supplemental Methods: including HUVEC fibrin gel bead assay, Production of anti-DLL4 F(ab')2, Mouse neonatal retina assay, Xenograft tumor models, Histological analysis of mouse liver, PK assay methods, and Anti-therapeutic antibody assay method. Table S1: PK parameters of anti-DLL4 IgG1 and F(ab')2 in mouse. Table S2: PK parameters for anti-DLL4 IgG1 and F(ab')2 in rat and money. Table S3: Summary of incidence of skin neoplasms in rats treated with anti-DLL4 IgG1 or anti-DLL4 F(ab')2. Figure S1: Generating and characterizing low affinity anti-DLL4 antibodies. Figure S2: Characterization of anti-DLL4 F(ab')2 using HUVEC bead sprouting assay. Figure S3: PK profile of anti-DLL4 IgG1 and F(ab')2 in rat toxicity studies. Figure S4. Mitigation of liver toxicity in mice with anti-DLL4 F(ab')2. Figure S5. Novel toxicities identified with anti-DLL4 F(ab')2 in rats.
Supplementary Table 2 from Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Authors: Parkin Brian , Ouillette Peter , Yildiz Mehmet , Saiya-Cork Kamlai , Shedden Kerby , Malek Sami N.
Published: April 2023

Supplementary Table 2. Detailed clinical characteristics of MI-AML patients.
Supplementary Legends from Integrated Genomic Profiling, Therapy Response, and Survival in Adult Acute Myelogenous Leukemia
Authors: Parkin Brian , Ouillette Peter , Yildiz Mehmet , Saiya-Cork Kamlai , Shedden Kerby , Malek Sami N.
Published: April 2023

Supplementary Legends
Supplementary Figure 4 from Not all NOTCH Is Created Equal: The Oncogenic Role of NOTCH2 in Bladder Cancer and Its Implications for Targeted Therapy
Authors: Hayashi Tetsutaro , Gust Kilian M. , Wyatt Alexander W. , Goriki Akihiro , Jäger Wolfgang , Awrey Shannon , Li Na , Oo Htoo Zarni , Altamirano-Dimas Manuel , Buttyan Ralph , Fazli Ladan , Matsubara Akio , Black Peter C.
Published: April 2023

NOTCH2-inactivating antibody inhibited tumor progression in vitro and in vivo.
Supplementary Figure S3 from Development of Engineered T Cells Expressing a Chimeric CD16-CD3ζ Receptor to Improve the Clinical Efficacy of Mogamulizumab Therapy Against Adult T-Cell Leukemia
Authors: Tanaka Hiroki , Fujiwara Hiroshi , Ochi Fumihiro , Tanimoto Kazushi , Casey Nicholas , Okamoto Sachiko , Mineno Junichi , Kuzushima Kiyotaka , Shiku Hiroshi , Sugiyama Takashi , Barrett A. John , Yasukawa Masaki
Published: April 2023

A representative case of aggressive ATL for which Mog treatment failed. (a) CD4+CD25+ ATL tumor cells in peripheral blood displayed CCR4. (b) Weekly administration of Mog a total of 3 times failed to suppress ATL disease activity, as represented by an increased LDH value. Thereafter, repeated intensive chemotherapy had been needed to suppress disease activity until allo-HSCT was conducted. At the same time, prolonged lymphocytopenia was noticeable. Clear triangles: lactate dehydrogenase (LDH); solid circles: lymphocyte count; Mog: mogamulizumab; white arrow: infusion of mogamulizumab; gray arrow: intensive chemotherapy. (c) Computed tomograms. Lt: on day -3 before start of Mog, and 26 days after three courses of the mLSG15 regimen24. No lymph node swelling is evident (complete remission). Rt: On day 16 after the start of Mog administration, enlarged lymph nodes were detected systemically (progressive disease), highlighted by yellow circles and yellow arrows.
Supplementary Data clean from Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate
Authors: Andronesi Ovidiu C. , Loebel Franziska , Bogner Wolfgang , Marjańska Małgorzata , Vander Heiden Matthew G. , Iafrate A. John , Dietrich Jorg , Batchelor Tracy T. , Gerstner Elizabeth R. , Kaelin William G. , Chi Andrew S. , Rosen Bruce R. , Cahill Daniel P.
Published: April 2023

This file contains 3 Tables and 9 Figures with additional results and details of analysis related to the main results presented in the manuscript. The complete list of figures and tables is provided below. Table 1S. Baseline metabolite levels relative to creatine. Table 2S. Demographic, genomic, molecular, histological, radiological and clinical data. Table 3S. Fractional changes for all imaging biomarkers. Table 4S. General Linear Model with change of KPS as dependent variable and grade, age and fractional volume of decreased 2HG/Cre as covariates. Figure 1S. 3D MRSI pulse sequence for 2HG imaging, detailed diagram. Figure 2S. Quantum mechanics simulations of 2HG spectral editing for MEGA-LASER, MEGA-PRESS and PRESS-97 sequences. Figure 3S. Simulations of 2HG editing for MEGA-LASER and PRESS-97 sequences in the presence of B1 field inhomogeneity. Figure 4S. Mitigation of subtraction artifacts caused by motion and scanner instability in J-difference MR spectroscopy using real-time prospective motion correction, shim update and reacquisition. Figure 5S. Metabolic maps before image interpolation. Figure 6S. Examples of OFF and difference (DIFF) MEGA-LASER spectra from 3D MRSI voxels located in the tumor and contralateral normal appearing white matter, pre- and post-treatment respectively. Figure 7S. Distributions of Î”2HG/Cre in the test-retest and post-pre longitudinal data sets. Figure 8S. Comparison of functional spectroscopic maps (fSM) and functional diffusion maps (fDM). Figure 9S. Relation between residual tumor measured by FLAIR hyperintensity volume and the SNR and CRLB of 2HG. Notes. Details related to data analysis in Figures 7S and 9S.
Supplementary Tables S6 and S7 from Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment, and Are Differentially Associated with Metastatic Prostate Cancer
Authors: Hurley Paula J. , Sundi Debasish , Shinder Brian , Simons Brian W. , Hughes Robert M. , Miller Rebecca M. , Benzon Benjamin , Faraj Sheila F. , Netto George J. , Vergara Ismael A. , Erho Nicholas , Davicioni Elai , Karnes R. Jeffrey , Yan Guifang , Ewing Charles , Isaacs Sarah D. , Berman David M. , Rider Jennifer R. , Jordahl Kristina M. , Mucci Lorelei A. , Huang Jessie , An Steven S. , Park Ben H. , Isaacs William B. , Marchionni Luigi , Ross Ashley E. , Schaeffer Edward M.
Published: April 2023

Supplementary Tables S6 shows bivariate analyses of the most common germline ASPN D genotypes/alleles for adverse pathology. Supplementary Table S7 shows multivariable analyses of ASPN D13/14 and Any 14 with lymph node involvement.
Supplementary Figure 1 from Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
Authors: Martens Alexander , Wistuba-Hamprecht Kilian , Foppen Marnix Geukes , Yuan Jianda , Postow Michael A. , Wong Phillip , Romano Emanuela , Khammari Amir , Dreno Brigitte , Capone Mariaelena , Ascierto Paolo A. , Di Giacomo Anna Maria , Maio Michele , Schilling Bastian , Sucker Antje , Schadendorf Dirk , Hassel Jessica C. , Eigentler Thomas K. , Martus Peter , Wolchok Jedd D. , Blank Christian , Pawelec Graham , Garbe Claus , Weide Benjamin
Published: April 2023

Detailed gating strategy for quantification of subsets of monocytes and myeloid-derived suppressor cells (MDSCs), T cells and regulatory T cells (Tregs). Total cells were selected by gating on Time vs. SSC-A. Duplicates were removed via progressive gating on FSC-H vs. FSC-A and SSC-H vs. SSC-A. Dead cells were excluded by considering only EMA-negative cells. (A) A lineage cocktail (CD3, CD19, CD56) was used to avoid cross-contamination. Previously described MDSC populations were identified as Lin-CD14+HLA-DRlow and Lin-CD14-CD15+CD11b+ within the all-cell gate. Overall monocytes were defined as CD14+, while subsets were separated into classical monocytes (Lin-CD14+CD16-HLA-DR+), non-classical monocytes (Lin-CD14-CD16+HLA-DR+) and Lin- CD14-CD16dimHLA-DR+ monocytes within the all-cell gate. (B) A morphological gate was used to identify the population of lymphocytes. Next, CD3+ cells were selected and further separated into CD4+ and CD8+ cells. Ki67 expression was investigated on CD4+ and CD8+ cells. CD8+ T cells with suppressive potential were defined as CD103+. Previously described phenotypes of Tregs were defined as CD4+CD25+FoxP3+ and CD4+CD127lowCD25+FoxP3+. These were further subdivided into proliferating (Ki67+CD45RA-) and non-proliferating Tregs (Ki67-CD45RA+).
Supplementary Video E from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary Video E. Physical health of mice group with tumor and with HERV-K env-specific CAR+ T-cell treatment.
Supplementary Video B from Genetic Engineering of T Cells to Target HERV-K, an Ancient Retrovirus on Melanoma
Authors: Krishnamurthy Janani , Rabinovich Brian A. , Mi Tiejuan , Switzer Kirsten C. , Olivares Simon , Maiti Sourindra N. , Plummer Joshua B. , Singh Harjeet , Kumaresan Pappanaicken R. , Huls Helen M. , Wang-Johanning Feng , Cooper Laurence J.N.
Published: April 2023

Supplementary Video B. VTLM single cell killing of 375 tumor cells by HERV-K env-specific CAR+ T cells
Supplemental Figure Legends from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Authors: Cui Di , Dai Jinlu , Keller Jill M. , Mizokami Atsushi , Xia Shujie , Keller Evan T.
Published: April 2023

Supplemental Figure Legends
Supplemental Fig. 3 from Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer
Authors: Cui Di , Dai Jinlu , Keller Jill M. , Mizokami Atsushi , Xia Shujie , Keller Evan T.
Published: April 2023

Supplemental Figure 3. PF-03084014 inhibits notch pathway in prostate cancer tumor xenografts in vivo.
Supplementary Table 1 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Table 1. Primers and probes used for qPCR
Supplementary Figure 7 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 7. Example FACS profiles for virus- or tumor-specific CD8+ cells.
Supplementary Information, tracked changes accepted from Clinical Trial of Oral Nelfinavir before and during Radiation Therapy for Advanced Rectal Cancer
Authors: Hill Esme J. , Roberts Corran , Franklin Jamie M. , Enescu Monica , West Nicholas , MacGregor Thomas P. , Chu Kwun-Ye , Boyle Lucy , Blesing Claire , Wang Lai-Mun , Mukherjee Somnath , Anderson Ewan M. , Brown Gina , Dutton Susan , Love Sharon B. , Schnabel Julia A. , Quirke Phil , Muschel Ruth , McKenna William G. , Partridge Michael , Sharma Ricky A.
Published: April 2023

Supplementary Table 1: Laboratory values (Liver Function Tests) Supplementary Table 2: Overview of mean pCT parameters for tumour VOI on sequential scans Supplementary Table 3: Overview of median DCE-MRI parameters, Ktrans, Ve and Kep for tumour VOI on sequential scans. Mean across all patients of the median per patient values is shown. Supplementary Table 4: Correlations of baseline characteristics, mutation status & overall mrTRG score with TCD. Supplementary Table 5 Correlations of baseline characteristics, mutation status & overall mrTRG score with median Ktrans. Supplementary Table 6: Correlations of baseline characteristics, mutation status & overall mrTRG score with mean Blood Flow. Supplementary Figure 1: Axial and sagittal images from T2W MRI scans at baseline and 8 weeks after completion of therapy. Supplementary Figure 2: Perfusion parameter maps illustrating an increase in Blood Flow and reduction in MTT between Scans 2 and 3. Supplementary Figure 3: Examples of (a) positive immunohistochemistry staining in pre-treatment rectal tumour biopsies and (b) absent staining in negative control.
Supplementary Figure 5 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 5. Analysis of B, Treg, NK and NKT cells in splenocytes of DT6606-OVA tumor-bearing mice after treatment.
Supplementary Table S1 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Table S1. Patient characteristics
Supplementary Figure 2 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 2. CD3+ CD8+ T cell infiltration into pancreatic tumors of KPC mice
Supplementary Figure 1 from A Vaccinia Virus Armed with Interleukin-10 Is a Promising Therapeutic Agent for Treatment of Murine Pancreatic Cancer
Authors: Chard Louisa S. , Maniati Eleni , Wang Pengju , Zhang Zhongxian , Gao Dongling , Wang Jiwei , Cao Fengyu , Ahmed Jahangir , El Khouri Margueritte , Hughes Jonathan , Wang Shengdian , Li Xiaozhu , Denes Bela , Fodor Istvan , Hagemann Thorsten , Lemoine Nicholas R. , Wang Yaohe
Published: April 2023

Supplementary Figure 1. Replication, potency and protein expression of IL-10 by VVLâˆ†TK and VVLâˆ†TK-IL-10 in vitro in PT45 cells
Supplementary Figure S2 from A Serum MicroRNA Signature Predicts Tumor Relapse and Survival in Triple-Negative Breast Cancer Patients
Authors: Kleivi Sahlberg Kristine , Bottai Giulia , Naume Bjørn , Burwinkel Barbara , Calin George A. , Børresen-Dale Anne-Lise , Santarpia Libero
Published: April 2023

Supplementary Figure S2. Hierarchical clustering of microRNA expression
Supplementary Tables 1-6 from RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer
Authors: Liang Qian , Ma Dan , Zhu Xiaoqiang , Wang Zhenhua , Sun Tian-Tian , Shen Chaoqin , Yan Tingting , Tian Xianglong , Yu TaChung , Guo Fangfang , Tang JiaYin , Lin Yanwei , Chen Huimin , Zhou Chao , Ge Zhizheng , Zhong Ming , Chen Jinxian , Liu Qiang , Wang Zheng , Fang Jing-Yuan , Chen Haoyan , Hong Jie
Published: April 2023

Table S1.Expression of human ubiquitin ligase genes in 246 CRC patients of TCGAdatabase.TableS2.Clinial information of 62 cases CRC patients (fresh tissues).Table S3.Clinial information of 78 cases CRC patients (paraffin tissues).Table S4.Clinial information of 97 cases CRC patients (paraffin tissues).Table S5.RNA sequence data. TableS 6. Primer sequences
Supplement Figures 1 - 5 and Tables 1 - 6 from Clinical Implications of Phosphorylated STAT3 Expression in De Novo Diffuse Large B-cell Lymphoma
Authors: Ok Chi Young , Chen Jiayu , Xu-Monette Zijun Y. , Tzankov Alexandar , Manyam Ganiraju C. , Li Ling , Visco Carlo , Montes-Moreno Santiago , Dybkær Karen , Chiu April , Orazi Attilio , Zu Youli , Bhagat Govind , Richards Kristy L. , Hsi Eric D. , Choi William W.L. , van Krieken J. Han , Huh Jooryung , Zhao Xiaoying , Ponzoni Maurilio , Ferreri Andrés J.M. , Bertoni Francesco , Farnen John P. , Møller Michael B. , Piris Miguel A. , Winter Jane N. , Medeiros L. Jeffrey , Young Ken H.
Published: April 2023

Supplementary Figure 1. Morphology and immunophenotype of pSTAT3+ DLBCL. Supplementary Figure 2. Relationship between STAT3 mRNA and pSTAT3 expression and survival analysis based on STAT3 mRNA level. Supplementary Figure 3. Survival analyses based on pSTAT3 expression in DLBCL with MYC/BCL2 double expression and DLBCL without MYC/BCL2 double expression after COO stratification. Supplementary Figure 4. Overall survival (OS) and progression-free survival (PFS) in all DLBCL cases, DLBCL with germinal center B-cell-like phenotype (GCB) and DLBCL with activated B-cell-like phenotype (ABC). Supplementary Figure 5. Survival analyses in 3 and 4 groups based on pSTAT3 expression in lymphoma cells. Supplementary Table 1. Number of cases based on pSTAT3 expression, MYC/BCL2 double expression and COO classification Supplementary Table 2. The numbers and percentages of pSTAT3 positive DLBCL with each cutoff Supplementary Table 3. Clinical characteristics and cell-of-origin differentiation with 30% cutoff for pSTAT3 expression Supplementary Table 4. Distribution of cell-of-origin classification based on 4 groups of pSTAT3 expression in lymphoma cells. Supplementary Table 5. Distribution of cell-of-origin classification based on 3 groups of pSTAT3 expression in lymphoma cells. Supplementary Table 6. Bivariate analyses of pSTAT3 with each variable and pSTAT3.
Supplementary Table 1 from Efficacy and Biological Activity of Imatinib in Metastatic Dermatofibrosarcoma Protuberans (DFSP)
Authors: Stacchiotti Silvia , Pantaleo Maria A. , Negri Tiziana , Astolfi Annalisa , Tazzari Marcella , Dagrada Gian Paolo , Urbini Milena , Indio Valentina , Maestro Roberta , Gronchi Alessandro , Fiore Marco , Dei Tos Angelo P. , Conca Elena , Palassini Elena , Vincenzi Bruno , Grosso Federica , Pilotti Silvana , Castelli Chiara , Casali Paolo G.
Published: April 2023

Supplementary Table 1. Supervised analysis highlighted the differential expression of 250 genes, with a p value <0.01 and two-fold difference